Corbus Pharmaceuticals Holdings Inc [CRBP] stock is trading at $42.39, up 6.59%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRBP shares have gain 13.80% over the last week, with a monthly amount glided 13.13%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Corbus Pharmaceuticals Holdings Inc [NASDAQ: CRBP] stock has seen the most recent analyst activity on March 06, 2024, when Jefferies upgraded its rating to a Buy and also boosted its price target to $46 from $4. Previously, ROTH Capital downgraded its rating to Neutral on September 08, 2020, and dropped its price target to $3. On September 08, 2020, downgrade downgraded it’s rating to Sector Perform. Jefferies downgraded its rating to a Hold and decreased its price target to $2.50 on September 08, 2020. BTIG Research downgraded its rating to a Neutral. ROTH Capital started tracking with a Buy rating for this stock on July 07, 2020, and assigned it a price target of $40. In a note dated June 17, 2020, BTIG Research initiated an Buy rating and provided a target price of $22 on this stock.
Corbus Pharmaceuticals Holdings Inc [CRBP] stock has fluctuated between $3.03 and $49.87 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Corbus Pharmaceuticals Holdings Inc [NASDAQ: CRBP] shares were valued at $42.39 at the most recent close of the market. An investor can expect a potential return of 8.52% based on the average CRBP price forecast.
Analyzing the CRBP fundamentals
Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -25.69%, Pretax Profit Margin comes in at -25.01%, and Net Profit Margin reading is -25.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -1.35 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.58 points at the first support level, and at 36.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.93, and for the 2nd resistance point, it is at 47.47.
Corbus Pharmaceuticals Holdings Inc [CRBP] reported earnings per share of -$0.83 for its fiscal quarter that ended on 3/31/2024. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.09/share, meaning a difference of $0.26 and a surprise factor of 23.90%. By comparison, the stated earnings for the previous quarter ended on 12/31/2023 were -$1.81 per share as compared to estimates of -$2.36 per share, a difference of $0.55 representing a surprise of 23.30%.
Ratios To Look Out For
For context, Corbus Pharmaceuticals Holdings Inc’s Current Ratio is 4.69. In addition, the Quick Ratio stands at 4.69 and the Cash Ratio stands at 0.54.
Transactions by insiders
Recent insider trading involved Cormorant Asset Management, LP, 10% Owner, that happened on Mar 08 ’24 when 0.3 million shares were purchased. 10% Owner, Cormorant Asset Management, LP completed a deal on Mar 07 ’24 to buy 0.25 million shares. Meanwhile, 10% Owner Cormorant Asset Management, LP bought 0.75 million shares on Feb 02 ’24.
